Introduction
============

The main characteristic of tumor cell resistance is MDR, in which cancer cells exhibit a cross-resistant phenotype against multiple unrelated drugs that are structurally and/or functionally different and may also have varying molecular targets ([@B35]). MDR is the main cause of the decline in clinical efficacy of chemotherapeutic drugs. There are several mechanisms that could cause MDR, such as reduced uptake of drugs, overexpression of energy-dependent efflux proteins, increased efflux of drugs by drug transporters, inhibition of apoptosis, activation of DNA repair mechanisms, cell cycle arrest and modification of cell cycle checkpoints ([@B14]; [@B17]; [@B19]; [@B29]). Among these, one of the most important mechanisms underlying MDR is the overexpression of the adenosine triphosphate (ATP)-binding cassette (ABC) super-family of transporters, which effectively pump out cytotoxic agents and targeted anticancer drugs across the cell membrane ([@B47]; [@B12]). ABC transporters that cause drug resistance are currently divided into three main categories: ABCB, ABCC, and ABCG. Among them, ABCB1 (P-glycoprotein, P-gp), ABCC1 (MDR protein 1, MRP1), and ABCG2 (breast cancer resistance protein, BCRP) are the most common ones ([@B38]; [@B26]).

P-gp was the first ABC transporter that was isolated from colchicine-resistant Chinese hamster ovary cells by [@B18]. P-gp pumps substrates out of tumor cells through an ATP-dependent mechanism ([@B18]; [@B20]; [@B24]). MRP1 was first reported in 1992 as the mediator of acquired drug resistance in a small cell lung cancer cell line selected by repeated exposure to doxorubicin ([@B8]; [@B13]). Although associated with drug resistance properties, it also has been identified as an organic anion transporter in its normal physiological role ([@B4]). BCRP, encoded by ABCG2, was the third member of the ABC transporter family that was identified ([@B10]; [@B27]; [@B32]). A number of chemotherapeutic agents, such as MX, 9-aminocamptothecin, topotecan, irinotecan and SN-38 have been shown to be transported by BCRP ([@B33]). ABC transporters mainly contribute to MDR by altering drug absorption, distribution, excretion and metabolism ([@B21]). Numerous studies have found that ABC transporters are over expressed in many tumor tissues. For this reason, reversal of MDR caused by ABC transporters is one of the main strategies for tumor treatment. Researchers have been working to find new ways to inhibit ABC transporters and re-sensitize cancer cells to chemotherapeutic drugs ([@B21]).

Tyrosine kinases (TKs) are widely expressed in cells, and they play important roles in various cellular processes. The expression of TKs is related to the proliferation, differentiation, migration, apoptosis, angiogenesis, and metastasis of cancer cells in key signaling events/pathways ([@B42]; [@B31]; [@B36]). The phosphatidyl inositol-3-kinase (PI3K)/AKT, protein kinase C (PKC) family, and mitogen-activated protein kinase (MAPK)/Ras signaling cascades are activated by TKs and play important roles in cell proliferation and homeostasis ([@B11]). TKs can catalyze the transfer of a phosphate group from ATP to target proteins. Therefore, TKIs have become one of the effective targets in cancer treatments ([@B9]; [@B34]). TKIs have achieved significant clinical efficacy as anti-tumor agents. Among them, small-molecule TK inhibitors are the most promising new drugs and have shown good prospects in both clinical and experimental treatments ([@B6]; [@B16]; [@B7]; [@B30]).

In recent years, studies have found that ABC transporters and several TKIs interact with each other (e.g., imatinib, sunitinib, nilotinib, and gefitinib). On the one hand, ABC transporters can cause a decrease in the function of TKIs, leading to the occurrence of MDR ([@B3]). Parts of TKIs can be the substrates of ABC transporters. The ABC transporters pump them out of the cell and cause drug resistance ([@B15]). On the other hand, more and more studies have shown that some TKIs can reverse ABC transporter--mediated MDR ([@B25]). The reversal mechanisms include inhibiting the protein expression of ABC transporters, inhibiting the protein pumping function and other signaling pathways ([@B44],[@B45]; [@B3]; [@B21]).

Olmutinib (HM61713/BI1482694) is a novel third-generation that is orally active and selectively inhibits EGFR mutations (**Figure [1](#F1){ref-type="fig"}**), including both activating mutations and T790M, but not EGFR wild-type ([@B23]). It was approved in South Korea on May 13, 2016 for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC previously treated with an EGFR TKI ([@B37]). At present, olmutinib is waiting for the phase III clinical efficacy observation.

![The chemical structure of olmutinib.](fphar-09-01097-g001){#F1}

Tyrosine kinase inhibitors may behave as substrates or inhibitors of ABC transporters depending on the expression of specific pumps, drug concentration, affinity for transporters and types of co-administered agents ([@B3]). Therefore, we performed *in vitro* experiments to evaluate if olmutinib could reverse MDR in cancer cells overexpressing ABCB1, ABCG2, or ABCC1 transporters.

Materials and Methods {#s1}
=====================

Chemicals and Reagents
----------------------

Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), bovine calf serum (BS), penicillin/streptomycin and trypsin 0.25% were purchased from Hyclone (GE Healthcare Life Sciences, Pittsburgh, PA, United States). 10X solution of phosphate buffered saline (PBS), SN-38, and Alexa Fluor 488 conjugated rabbit anti-mouse IgG secondary antibody were purchased from Thermo Fisher Scientific Inc. (Rockford, IL, United States). The monoclonal antibodies for ABCG2 (BXP-34), paclitaxel, vincristine, vinblastine, cisplatin, MX, verapamil, 3-(4, 5-dimethylthiazol-yl)-2, 5-diphenyltetrazolium bromide (MTT), dimethyl sulfoxide (DMSO), propidium iodide (PI), and Triton X-100, were obtained from Sigma Chemical Co. (St. Louis, MO, United States). Ko-143 and MK-571 were products from Enzo Life Sciences (Farmingdale, NY, United States). Monoclonal antibodies sc-47778 (against β-actin) and secondary HRP-labeled rabbit anti-mouse IgG were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, United States). \[^3^H\]- MX) (2.5 Ci/mmol) was purchased from Moravek Biochemicals (Brea, CA, United States). Liquid scintillation cocktail was a product from MP Biomedicals, Inc. (Santa Ana, CA, United States). All other chemicals were purchased from Sigma Chemical Co. (St. Louis, MO, United States).

Cell Lines and Cell Culture
---------------------------

The non-small cell lung cancer cell line NCI-H460 and its drug-resistant ABCG2-overexpressing NCI-H460/MX20 cells, which was maintained in medium with an addition of 20 nM MX, were kindly provided by Drs. Susan Bates and Robert Robey (NIH, Bethesda, MD, United States). The human epidermal carcinoma cell line KB-3-1 and its drug-resistant ABCB1-overexpressing KB-C2 cells, which were cloned from KB-3-1 and maintained in medium with 2 mg/ml of colchicine, and its drug-resistant ABCC1-overexpressing cell line KB-CV60, maintained in medium with 1 μg/mL of cepharanthine and 60 ng/mL of vincristine, were also used in this study ([@B2]). HEK293/pcDNA3.1, HEK293/ABCB1, HEK293/ABCG2, and HEK293/ABCC1 cells lines were established by transfecting HEK293 cells with either the empty pcDNA3.1 vector or the vector containing full length ABCB1 (HEK293/ABCB1), ABCG2 (HEK293/ABCG2), and ABCC1 (HEK293/ABCC1) DNA, respectively, and were cultured in medium containing 2 mg/mL of G418 (Enzo Life Sciences, Farmingdale, NY, United States) ([@B46]). All cell lines were cultured in DMEM medium with 10% FBS and 1% penicillin/streptomycin at 37°C with 5% CO~2~. All drug-resistant cell lines were grown in a drug-free culture medium for more than 2 weeks prior to use.

Cell Cytotoxicity by MTT Assay
------------------------------

The cytotoxicity of anticancer drugs with or without modulator agents was determined by modified MTT colorimetric assay ([@B12]). Briefly, 5000 cells were seeded evenly into each well in coated 96-well microplates overnight. Olmutinib and parallel control modulators were added 2 h prior to the addition of chemotherapeutic drugs in a designated concentration gradient. After 68 h of incubation, 20 μL of MTT solution (4 mg/mL) was added into each well with further incubation of 4 h. The medium was aspirated and 100 μL of DMSO was added to dissolve the formazan crystals in each well. The absorbance was determined at 570 nm by the accuSkan GO UV/Vis Microplate Spectrophotometer (Fisher Scientific, Fair Lawn, NJ, United States). Verapamil, KO-143 and MK-571 was used as a inhibitors for ABCB1-overexpressing, ABCG2-overexpressing, and ABCC1-overexpressing cell lines, respectively.

Western Blotting Analysis
-------------------------

After treatment with 0, 3, and 6 μM olmutinib for 72 h, and after treatment with 3 μM olmutinib for 24, 48, and 72 h in NCI-H460/MX20 cells, the cells were incubated with a lysis buffer (2.5% 1M Tris, 0.15% EDTA, 1% sodium deoxycholate, 0.1% SDS, 0.88% NaCl, 1% Triton-X and protease inhibitor cocktail) on ice for 20 min, followed by centrifugation at 12,000 *g* at 4°C for 20 min. The supernatant was collected, and the protein concentration was determined by a bicinchoninic acid (BCA)-based protein assay (Thermo Scientific, Rockford, IL, United States). 25 μg of protein in 30 μl loading sample was separated by SDS-polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride (PVDF) membrane. After blocked by 5% dry milk for 2 h, the membrane was incubated with primary antibody BXP-34 (1:1000, detects BCRP) overnight at 4°C. The signal was detected using enhanced chemiluminescence followed by incubation with secondary HRP-labeled antibody (1:1000). The protein expression was quantified by ImageJ software (NIH, Bethesda, MD, United States).

Immunofluorescence Assay
------------------------

NCI-H460 and NCI-H460/MX20 cells were seeded as 1 × 10^5^ per well in 24-well plates and cultured at 37°C for 24 h, followed by incubation with 3 μM olmutinib for 0, 24, 48, and 72 h, or followed by incubation with 0, 1, 3, or 6 μM olmutinib. The cells were then washed with cold PBS solution twice and fixed in 4% formaldehyde for 15 min. Subsequently, after incubation with 0.5% Triton X-100 for 15 min, cells were incubated with BSA (2 mg/ml) for 1 h followed by monoclonal antibodies for ABCG2 (BXP-34, 1:1000) overnight at 4°C. Cells were further incubated with Alexa Fluor 488 conjugated IgG secondary antibody for 1 h in dark. PI solution was used to counterstain the nuclei. Immunofluorescence images were collected using a Nikon TE-2000S fluorescence microscope (Nikon Instruments Inc., Melville, NY, United States).

ABCG2 ATPase Assay
------------------

The ABCG2 ATPase activity based on vanadate-sensitive membrane vesicles of High Five insect cells was measured as previously described ([@B47]). Briefly, the membrane vesicles (10 μg of protein) were incubated in ATPase assay buffer with or without 0.3 mM vanadate at 37°C for 5 min. After that, the assay buffer was incubated with 0--40 μM varying concentrations of olmutinib at 37°C for 3 min. The ATPase reaction was induced by adding 5 mM MgATP with a total volume of 0.1 ml. After 20 min incubation at 37°C, the reaction was stopped by adding 100 μl 5% SDS solution to the reaction mix. The ATPase activity due to ABCG2 is calculated from the amount of inorganic phosphate (IP) released detected at 880 nm using a spectrophotometer.

Accumulation and Efflux Assay
-----------------------------

We used the drug accumulation and efflux assays as previously described ([@B12]). For the accumulation assay, NCI-H460 and NCI-H460/MX20 cells were seeded into 24-well plate (100,000 cells/well) and incubated at 37°C for 12 h. Then the cells were incubated with or without inhibitors for 2 h. The medium was discarded, followed by the addition of medium containing 0.01 μM \[^3^H\]-MX, and then the inhibitors were added into the wells. After 2 h incubation, the medium was discarded and the cells were washed with ice-cold PBS three times, lysed, and then transferred to the scintillation fluid. For the efflux assay, we performed similar procedures as the accumulation assay. After discarding the medium containing \[^3^H\]-MX, the cells were washed with ice-cold PBS and incubated with medium in the absence or presence of inhibitors. The cells were washed three times, lysed, and then transferred to the scintillation fluid at different time points of 0, 30, 60, and 120 min, respectively. The radioactivity was measured using the Packard TRI-CARB1 190'A liquid scintillation analyzer.

Molecular Modeling
------------------

Molecular modeling was performed in Maestro v11.1 (Schrödinger, LLC) software as described previously ([@B47]). Human ABCG2 (PDB ID: 5NJ3) ([@B41]) protein preparation was performed and the grid was generated by selecting residues (Phe432, Phe 439, Leu539, Ile543, Val546, and Met549) at a substrate-binding pocket in TMD of ABCG2. The best-scored ligand was obtained through Glide XP docking then the receptor grid for IFD was generated. The IFD protocol with default parameters was performed. The conformation of ligand with the highest docking score (kcal/mol) was used for docking analysis.

Statistical Analysis
--------------------

All experiments were repeated at least three times and the result values are presented as mean ± SD. Statistical differences between two groups were determined by the two-tailed Student's *t*-test and p values equal or below 0.05 were considered significant.

Results
=======

Effects of Olmutinib on Cells Overexpressing ABCB1, ABCG2, and ABCC1 Transporters
---------------------------------------------------------------------------------

To determine the effects of olmutinib on ABC transporters, the sensitivity of ABCB1-, ABCG2-, and ABCC1-overexpressing cells to olmutinib were determined. The cytotoxicity assay indicated that the IC~50~ values of olmutinib for ABCB1-, ABCG2-, and ABCC1-overexpressing cancer cells (KB-C2, NCI-H460/MX20 and KB-CV60) were 11.42, 12.19, and 17.14 μM. The IC~50~ values of olmutinib for their parental cells (KB-3-1, NCI-H460, and KB-3-1) were 18.85, 15.58, and 12.62 μM, respectively, (**Figure [2](#F2){ref-type="fig"}**). As the concentration of 3 μM olmutinib did not produce significant cytotoxicity, this concentration was used for reversal experiments.

![The concentration-survival curve of olmutinib on drug-induced ABCB1-, ABCG2-, and ABCC1-overexpressing cell lines and transfected ABCB1-, ABCG2-, and ABCC1-overexpressing cell lines. **(A)** Concentration-survival curves of KB-3-1 and KB-C2 cell lines incubated only with olmutinib. **(B)** Concentration-survival curves of NCI-H460 and NCI-H460/MX20 cell lines incubated only with olmutinib. **(C)** Concentration-survival curves of KB-3-1 and KB-CV60 cell lines incubated only with olmutinib. **(D)** Concentration-survival curves of HEK293/pcDNA3.1, HEK293/G2, HEK293/ABCB1, and HEK293/MRP1 cell lines incubated only with olmunitib. Each cell line was incubated with a designated concentration gradient of olmunitib for 72 h.](fphar-09-01097-g002){#F2}

Effects of Olmutinib on Reversing Drug-Resistance of ABCG2-Overexpressing Cells
-------------------------------------------------------------------------------

To further determine whether olmutinib in the above cell lines reverses the multi-drug resistance (MDR) mediated by ABC transporters, the drug-induced resistant human cancer cell line (KB-C2, NCI-H460/MX20, and KB-CV60) and the transfected resistant cell line (HEK293/ABCB1, HEK293/G2, and HEK293/MRP1) and their corresponding parental cell lines (KB-3-1, NCI-H460, and HEK293/pcDNA3.1) were used to perform the cytotoxicity assay. As shown in **Tables [1](#T1){ref-type="table"}**--**[3](#T3){ref-type="table"}**, the IC~50~ values of KB-C2 and KB-CV60 cell lines were much higher than those of the corresponding parental cell lines. On the other hand, the result in the NCI-H460/MX20 cell line was the opposite. As compared with the NCI-H460 and HEK293/pcDNA3.1 cell lines, olmutinib significantly decreased the IC~50~ values of MX and SN-38 in the NCI-H460/MX20 and HEK293/ABCG2 cell lines, but it did not affect the values of paclitaxel and vincristine in the KB-C2 and HEK293/ABCB1 cell lines, compared to parental KB-3-1 and HEK293/pcDNA3.1 cell lines. It also did not affect the IC~50~ values of vinblastine and vincristine in KB-CV60 and HEK293/MRP1 cell lines, compared to parental KB-3-1 and HEK293/pcDNA3.1 cell lines. Cisplatin is not a substrate for ABCB1 and ABCG2. It has no reversal effect on ABCB1-mediated and ABCG2-mediated MDR. So there was no significant change in the IC~50~ values of cisplatin in the human cancer cell lines (KB-C2, NCI-H460/MX20, and KB-CV60) or transfected cell lines (HEK293/ABCB1, HEK293/G2, and HEK293/MRP1) compared with the corresponding parental cells (**Tables [1](#T1){ref-type="table"}**--**[3](#T3){ref-type="table"}**). These results indicate that olmutinib could selectively reverse MDR mediated by ABCG2-overexpression but could not reverse ABCB1- and ABCC1-overexpressing mediated MDR.

###### 

The effect of olmutinib on drug resistance to paclitaxel, vincristine, and cisplatin in ABCB1-overexpressing cell lines (KB-3-1 and KB-C2, HEK293/pcDNA3.1, and HEK293/ABCB1).

  Treatment             IC~50~ ± SD^a^ (RF^b^)                                                    
  --------------------- ------------------------ -------------------------- --------------------- -------------------------
  **Paclitaxel**        0.034 ± 0.007(1.00)      2.389 ± 0.541(70.26)       0.173 ± 0.072(1.00)   4.464 ± 0.466(25.80)
  \+ Olmutinib (1 μM)   0.038 ± 0.009(1.12)      2.237 ± 0.487(65.79)       0.158 ± 0.025(0.91)   3.653 ± 1.096(21.12)
  \+ Olmutinib (3 μM)   0.036 ± 0.007(1.06)      2.174 ± 0.641(63.94)       0.134 ± 0.074(0.77)   3.462 ± 0.981(20.01)
  \+ Verapamil (3 μM)   0.054 ± 0.016(1.59)      0.495 ± 0.144(14.56)^∗∗^   0.153 ± 0.146(0.88)   0.263 ± 0.034(1.52)^∗∗^
  **Vincristine**       0.028 ± 0.006(1.00)      1.299 ± 0.361(46.39)       0.086 ± 0.221(1.00)   0.763 ± 0.647(8.87)
  \+ Olmutinib (1 μM)   0.024 ± 0.006(0.86)      1.217 ± 0.389(43.46)       0.071 ± 0.016(0.83)   0.733 ± 0.068(8.52)
  \+ Olmutinib (3 μM)   0.021 ± 0.007(0.75)      1.132 ± 0.238(40.43)       0.063 ± 0.017(0.73)   0.651 ± 0.692 (7.57)
  \+ Verapamil (3 μM)   0.032 ± 0.015(1.14)      0.056 ± 0.011(2.00)^∗∗^    0.077 ± 0.013(0.90)   0.126 ± 0.051(1.47)
  **Cisplatin**         1.194 ± 0.876(1.00)      1.863 ± 0.428(1.56)        1.523 ± 0.285(1.00)   1.945 ± 0.876(1.28)
  \+ Olmutinib (3 μM)   1.123 ± 0.473(0.94)      1.346 ± 0.283(1.13)        1.433 ± 0.465(0.94)   1.683 ± 0.464(1.11)
  \+ Verapamil (3 μM)   1.744 ± 0.452(1.46)      1.643 ± 0.233(1.38)        1.245 ± 0.337(0.82)   1.534 ± 0.344(1.01)

a
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values represent the mean ± SD of three independent experiments which were performed in triplicate.

b

Resistance Fold (RF) was calculated by dividing the IC

50

values of substrates in the presence or absence of an inhibitor by the IC

50

values of parental cells without an inhibitor.

∗∗

P \< 0.01 versus no inhibitor group.

###### 

The effect of olmutinib on drug resistance to MX, SN38, and cisplatin in ABCG2-overexpressing cell lines (NCI-H460 and NCI-H460/MX20, and HEK293/pcDNA3.1 and HEK293/ABCG2).

  Treatment                         IC~50~ ± SD^a^ (RF^b^)                                                     
  --------------------------------- ------------------------ ------------------------- ----------------------- -------------------------
  **MX**                            22.987 ± 4.145(1.00)     2.327 ± 0.642(101.23)     72.245 ± 10.834(1.00)   1.974 ± 0.846(27.32)
  \+ Olmutinib (1 μM)               18.642 ± 4.101(0.81)     0.039 ± 0.009(1.70)^∗∗^   70.563 ± 20.169(0.98)   0.261 ± 0.052(3.61)^∗^
  \+ Olmutinib (3 μM)               17.067 ± 2.241(0.74)     0.027 ± 0.017(1.17)^∗∗^   68.125 ± 14.824(0.94)   0.146 0.038(2.02)^∗^
  \+ Ko 143 (3 μM)                  16.947 ± 2.643(0.74)     0.022 ± 0.012(0.96)^∗∗^   62.234 ± 11.216(0.86)   0.183 ± 0.022(2.53)^∗^
  **SN-38**                         13.454 ± 1.156(1.00)     2.197 ± 0.342(163.30)     56.462 ± 9.243(1.00)    2.389 ± 0.279(42.31)
  \+ Olmutinib (1 μM)               12.592 ± 2.392(0.94)     0.033 ± 0.012(2.45)^∗∗^   56.427 ± 10.421(1.00)   0.288 ± 0.038(5.10)^∗∗^
  \+ Olmutinib (3 μM)               12.346 ± 3.243(0.92)     0.019 ± 0.034(1.41)^∗∗^   54.364 ± 5.826(0.96)    0.176 ± 0.029(3.12)^∗∗^
  \+ Ko 143 (3 μM)                  12.456 ± 4.024(0.93)     0.021 ± 0.032(1.56)^∗∗^   57.522 ± 8.024(1.02)    0.164 ± 0.027(2.90)^∗∗^
                                                                                                               
  **IC~50~ ± SD^a^ (μM) (RF^b^)**                                                                              
                                                                                                               
  **Cisplatin**                     1.426 ± 0.543(1.00)      1.745 ± 0.224(1.22)       1.628 ± 0.252(1.00)     1.463 ± 0.663(0.90)
  \+ Olmutinib (3 μM)               1.313 ± 0.512(0.92)      1.654 ± 0.443(1.16)       1.214 ± 0.478(0.75)     1.126 ± 0.275(0.69)
  \+ Ko 143 (3 μM)                  1.226 ± 0.861(0.86)      1.494 ± 0.268(1.05)       1.354 ± 0.368(0.83)     1.425 ± 0.264(0.88)

a

IC

50

values represent the mean ± SD of three independent experiments which were performed in triplicate.

b

Resistance Fold (RF) was calculated by dividing the IC

50

values of substrates in the presence or absence of an inhibitor by the IC

50

values of parental cells without an inhibitor.

∗

P \< 0.05,

∗∗

P \< 0.01 versus no inhibitor group.

###### 

The effect of olmutinib on drug resistance to vincristine, vinblastine, and cisplatin in ABCC1-overexpressing cell lines (KB-3-1and KB-CV60, HEK293/pcDNA3.1, and HEK293/ABCC1).

  Treatment                         IC~50~ ± SD^a^ (RF^b^)                                                     
  --------------------------------- ------------------------ -------------------------- ---------------------- --------------------------
  **Vincristine**                   18.424 ± 1.783(1.00)     253.243 ± 11.45(13.75)     13.254 ± 1.884(1.00)   258.344 ± 16.76(19.49)
  \+ Olmutinib (1 μM)               17.019 ± 2.354(0.92)     230.565 ± 14.081(12.51)    13.136 ± 2.372(0.99)   221.357 ± 20.731(16.70)
  \+ Olmutinib (3 μM)               16.564 ± 2.165(0.90)     224.363 ± 13.47(12.18)     12.136 ± 2.565(0.92)   213.564 ± 18.672(16.11)
  \+ MK 571 (25 μM)                 17.434 ± 1.624(0.95)     22.467 ± 9.744(1.22)^∗∗^   11.457 ± 1.343(0.86)   45.348 ± 7.238(3.42)^∗∗^
  **Vinblastine**                   56.514 ± 9.584(1.00)     275.345 ± 13.545(4.87)     8.864 ± 0.843(1.00)    58.462 ± 6.453(6.60)
  \+ Olmutinib (1 μM)               56.235 ± 7.956(1.00)     234.864 ± 18.452(4.16)     8.233 ± 0.571(0.93)    46.892 ± 7.563(5.29)
  \+ Olmutinib (3 μM)               56.184 ± 4.763(0.99)     213.585 ± 10.842(3.80)     8.164 ± 0.263(0.92)    45.364 ± 6.837(5.12)
  \+ MK 571 (25 μM)                 45.527 ± 6.254(0.81)     75.613 ± 8.124(1.34)^∗∗^   7.852 ± 0.144(0.89)    9.823 ± 0.453(1.11)^∗∗^
                                                                                                               
  **IC~50~ ± SD^a^ (μM) (RF^b^)**                                                                              
                                                                                                               
  **Cisplatin**                     1.683 ± 0.562(1.00)      1.896 ± 0.323(1.13)        1.644 ± 0.253(1.00)    1.864 ± 0.362(1.13)
  \+ Olmutinib (3 μM)               1.724 ± 0.233(1.02)      1.657 ± 0.546(0.98)        1.775 ± 0.265(1.08)    1.626 ± 0.164(0.99)
  +MK 571 (25 μM)                   1.326 ± 0.364(0.79)      1.469 ± 0.328(0.87)        1.527 ± 0.263(0.93)    1.454 ± 0.246(0.88)

a

IC

50

values represent the mean ± SD of three independent experiments which were performed in triplicate.

b

Resistance Fold (RF) was calculated by dividing the IC

50

values of substrates in the presence or absence of an inhibitor by the IC

50

values of parental cells without an inhibitor.

∗∗

P \< 0.01 versus no inhibitor group.

Effect of Olmutinib on the Protein Expression of ABCG2 Transporters
-------------------------------------------------------------------

Western blot analysis was performed to confirm whether olmutinib could affect the protein expression of ABCG2 transporters in cell lysates. As shown in **Figures [3A,C](#F3){ref-type="fig"}**, different concentrations (1, 3, and 6 μM) of olmutinib treatment did not significantly alter the expression of the ABCG2 protein (72 kDa) in ABCG2-overexpressing NCI-H460/MX20 cell line compared to control. **Figures [3B,D](#F3){ref-type="fig"}** indicated that the protein expression level of ABCG2 was quite low in the parental NCI-H460 cell line, and the treatment of olmutinib (3 μM) for 0, 24, 48, and 72 h did not significantly alter expression of the ABCG2 protein (72 kDa) in the ABCG2-overexpressing NCI-H460/MX20 cell line.

![Western blotting to detect ABCG2 expression in ABCG2-over-expressing cell lines. **(A)** The effect of olmutinib at 1, 3, and 6 μM on the expression levels of ABCG2 in NCI-H460 and NCI-H460/MX20 cells at 72 h. **(B)** The effect of olmutinib at 3 μM on the expression levels of ABCG2 in NCI-H460 and NCI-H460/MX20 cells at 0, 24, 48, and 72 h. **(C)** The effect of olmutinib at 0, 1, 3, and 6 μM on the expression levels of ABCG2 in NCI-H460 and NCI-H460/MX20 cells at 72 h. **(D)** The effect of olmutinib at 3 μM on the expression levels of ABCB1 in NCI-H460 and NCI-H460/MX20 cells at 0, 24, 48, and 72 h. Equal amounts of total cell lysate were used for each sample. ^∗^*P* \< 0.05 versus the control group (**B,D** versus NCI-H460).](fphar-09-01097-g003){#F3}

Effect of Olmutinib on the Expression and Intracellular Localization of ABCG2
-----------------------------------------------------------------------------

To further confirm whether olmutinib altered the expression and cellular localization of the ABCG2 protein, immunofluorescence staining was performed after cells were processed with different time of incubation or with different concentrations of olmutinib. As shown in **Figure [4](#F4){ref-type="fig"}**, the ABCG2 transporters are located on the membrane of NCI-H460/MX20 cells. **Figure [4A](#F4){ref-type="fig"}** showed that incubation of cells with 3 μM of olmutinib did not significantly alter the subcellular distribution of ABCG2 in NCI-H460/MX20 cells when compared at 0, 24, 48, and 72 h. Similarly, **Figure [4B](#F4){ref-type="fig"}** showed that incubation of cells after 72 h with 0, 1, 3, and 6 μM of olmutinib did not significantly alter the subcellular distribution of ABCG2 in NCI-H460/MX20 cells.

![Effect of olmutinib on the expression and cell localization of ABCG2. **(A)** Micrographs are representatives of immunostaining of NCI-H460/MX20 cells incubated with 3 mM olmutinib after 0, 24, 48, and 72 h. **(B)** The effect of olmutinib at 0, 1, 3, and 6 mM on NCI-H460/MX20 cells after being processed for 72 h.](fphar-09-01097-g004){#F4}

Effect of Olmutinib on \[^3^H\]-MX Accumulation and Efflux
----------------------------------------------------------

The accumulation and efflux effects of the olmutinib were investigated by comparing the quantity of \[^3^H\]-MX in NCI-H460 and ABCG2-mediated NCI-H460/MX20 cells. As shown in **Figure [5A](#F5){ref-type="fig"}**, intracellular \[^3^H\]-MX level in NCI-H460/MX20 cells was approximately 2.5-fold lower than that in NCI-H460 cells after 2 h incubation without an inhibitor. Compared with the control group, the accumulation of \[^3^H\]-MX in NCI-H460/MX20 cells was significantly increased in the olmutinib (3 μM) group. The accumulation effect of olmutinib (3 μM) is comparable to that of Ko 143 (3 μM), which is a positive inhibitor of ABCG2. **Figure [5B](#F5){ref-type="fig"}** indicated that the intracellular \[^3^H\]-MX level in NCI-H460 cells did not significantly change after 120 min, and treatment with inhibitors did not alter the efflux function in NCI-H460 cells. However, the intracellular \[^3^H\]-MX level in NCI-H460/MX20 cells decreased dramatically by about 60% without the treatment of inhibitors (**Figure [5C](#F5){ref-type="fig"}**). With the treatment of olmutinib (3 μM), the efflux function of NCI-H460/MX20 cells could be effectively inhibited; this inhibition of efflux function would increase with olmutinib at 6 μM.

![Effects of olmutinib on intracellular accumulation and efflux of \[^3^H\]-MX in NCI-H460 and NCI-H460/MX20 cells. **(A)** The effects of olmutinib on the accumulation of \[^3^H\]-MX in NCI-H460 and NCI-H460/MX20 cells. **(B)** The effects of olmutinib on the efflux function of NCI-H460 cells. **(C)** The effects of olmutinib on the efflux function of NCI-H460/MX20 cells. Error bars represent the SD value. Ko 143 (3 μM) is used as positive control for ABCG2-overexpressing cells. ^∗^*P* \< 0.05 versus control group, two-way ANOVA.](fphar-09-01097-g005){#F5}

Effect of Olmutinib on ATPase Activity of ABCG2 Transporters
------------------------------------------------------------

ABCG2-mediated ATP hydrolysis, in the presence of olmutinib at various concentrations from 0 to 40 μM, was measured to assess the effect of olmutinib on the ATPase activity of ABCG2. Olmutinib stimulated the ATPase activity of ABCG2 in a concentration-dependent manner, with a maximal stimulation of 3.5-fold of the basal activity as shown in **Figure [6](#F6){ref-type="fig"}**. The concentration of olmutinib required to obtain 50% stimulation is 2.2 μM. This result indicated that olmutinib interacts at the drug-substrate binding site and affects the ATPase activity of ABCG2.

![ABCG2 transporter specific ATPase activity was stimulated by olmutinib. The effect of olmutinib on the subcellular localization of BCRP in NCI-H460/MX20 cells. The graph shows that ATPase activity was plotted with SD as a function of concentration of olmutinib. The inset shows stimulation of ATP hydrolysis at lower (0--10 μM) concentration of olmutinib.](fphar-09-01097-g006){#F6}

Docking Analysis of the Binding of Olmutinib With Human Wild-Type ABCG2 Model
-----------------------------------------------------------------------------

The best-scored docked (-10.902 kcal/mol) position of olmutinib within the binding pocket of human ABCG2 (5NJ3) is shown in **Figure [7](#F7){ref-type="fig"}**. **Figure [7A](#F7){ref-type="fig"}** showed that there were two hydrogen bonds and one π -- π interaction between olmutinib and human ABCG2. Interestingly, the nitrogen in piperazine group of olmutinib was ionized and formed a hydrogen bond with Asn436 in the A chain. It was reported that acidic microenvironment is a major feature of tumor ([@B22]). Acidic extracellular pH could facilitate the ionization of olmutinib and generate the hydrogen bonding with ABCG2. The nitrogen in the enamide group of olmutinib could have another hydrogen bonding with Asn436 in the B chain of ABCG2. Besides the interactions mentioned above, olmutinib could be stabilized in the hydrophobic pocket of ABCG2 by the hydrophobic interactions with residues such as Met431, Phe432, Ile543, Phe549, and Leu555.

![The docking simulation of olmutinib with human ABCG2. **(A)** The two-dimensional ligand--receptor interaction diagram of olmutinib and human ABCG2. The amino acids within 4 Å are shown as colored bubbles, cyan indicates polar residues, and green indicates hydrophobic residues. Hydrogen bonds are shown by the purple dotted arrow. **(B)** Docked position of olmutinib within the binding site of human ABCG2. Olmutinib is shown as ball and stick mode with the atoms colored: carbon -- cyan, hydrogen -- white, nitrogen -- blue, oxygen -- red, and sulfur -- yellow. Important residues are shown as sticks with the same color mode as above except that carbons are colored in gray.](fphar-09-01097-g007){#F7}

Discussion
==========

According to previous studies, small molecule cell signaling inhibitors, such as TK inhibitors, are of crucial importance in chemotherapeutic drug resistance ([@B43]). ABC transporters are known as mediators of MDR, which is significantly reversed by many clinically used TKIs. Cancer cells acquire MDR via various types of ABC transporters; for example NSCLC cells obtain MDR due to overexpression of ABCG2. ABC transporter-mediated MDR has been found partially or completely reversed by other TKIs such as fumitremorgin C (FTC) ([@B23]). As a third-generation EGFR TKI, olmutinib has been approved for the treatment of locally advanced or metastatic EGFR T790M mutation-positive NSCLC ([@B28]). Therefore, in this study, we aimed to further explore whether olmutinib has potential reversal effects in different types of ABC transporter-mediated MDR. The results indicated that olmutinib greatly reversed ABCG2-mediated MDR, while ABCB1- and ABCC1-mediated MDR were not significantly influenced.

According to our MTT assay, MX-selected NCI-H460/MX20 cells also acquired resistance to SN-38 and were sensitized to both MX and SN-38 by incubation with olmutinib. IC~50~ of cisplatin, which is not a substrate of ABCG2, did not vary significantly with or without pre-incubation with olmutinib. To further explore the specificity of its reversal effects, we also determined the effects of olmutinib on ABCB1-overexprssing cells. Both ABCB1-transfected HEK293 cell and colchicine-selected ABCB1-overexpressing KB-C2 cells had shown drug resistance toward paclitaxel and vincristine. After olmutinib incubation, the results showed that ABCB1-overexpressing cells were not significantly sensitized. Similarly, olmutinib did not show statistically significant reversal effects in ABCC1-overexpressing KB-CV60 and HEK293/ABCC1 cells.

Moreover, to explore the possible mechanism of olmutinib, its effect on ABCG2 expression was tested. Based on the result, ABCG2 expression was not significantly altered with different incubation time or olmutinib concentration. Additionally, intracellular localization of ABCG2 did not vary after 72 h of treatment, as demonstrated by the immunofluorescence results. Based on these findings, we can conclude that the reversal of drug resistance by olmutinib is not related to down-regulated ABCG2 protein expression or altered intracellular location. Instead, the reversal function of olmutinib may be generated by interacting with the ABCG2 protein.

To further determine the interaction between olmutinib and ABCG2, we investigated the accumulation/efflux effect of olmutinib. The results indicated a significant increase in \[^3^H\]-MX accumulation in NCI-H460MX20 cells when incubated with 3 μM olmutinib. The accumulation effect of olmutinib was comparable to that of a positive ABCG2 inhibitor Ko 143. In addition, according to the efflux time-course, MDR cells showed an inhibited MX efflux when treated with olmutinib compared with control group. In conclusion, olmutinib reversed ABCG2-mediated MDR due to inhibited drug efflux, leading to an increased intracellular drug accumulation. A large proportion of TKIs that are involved in ABC transporter-mediated MDR reversal stimulate ATP hydrolysis ([@B1]); we saw consistent results in the ATPase assay that olmutinib stimulated ATPase activity of ABCG2 up to 3.5-fold. Additionally, the molecular interaction between olmutinib and ABCG2 was identified by a docking simulation. The best-score (-10.902 kcal/mol) docking position of olmutinib within human ABCG2 implied direct interaction with π -- π bonds and hydrogen bonds, which stabilized olmutinib in the hydrophobic pocket of ABCG2. The results showed that olmutinib not only interacts directly with ABCG2 but also works as a competitive inhibitor of the transport protein. In conclusion, the reversal effect of olmutinib on ABCG2 in MDR cells is not due to ABCG2 expression or intracellular localization, but is related to its interaction with the ABCG2 protein including drug efflux inhibition and ATPase stimulation.

The mechanism involved in resistance of olmutinib is very complex. In recent years, some studies have shown that the nucleotide polymorphism of ABCG2 gene may play a role in the expression level and function of ABCG2 ([@B39]; [@B5]; [@B40]). In addition, the nucleotide polymorphism of ABCG2 gene is also associated with drug resistance. Therefore, the effect of ABCG2 single nucleotide polymorphism on ABCG2 function, pharmacokinetics and the mechanism of ABCG2 effect on tumor will be the focus of our future research.

Conclusion
==========

Overall, in this study we reported that a newly approved TKI olmutinib reversed ABCG2-mediated MDR by inhibiting chemotherapeutic drug efflux and increasing intracellular drug accumulation. Collectively, our study suggested that ABCG2-mediated drug resistance to conventional chemotherapeutic drugs could be reversed by a combination regimen of olmutinib with other chemotherapeutic drugs.
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